Suppr超能文献

肿瘤相关巨噬细胞上的Siglec10表达是Ⅰ期肺腺癌的独立预后因素。

Siglec10 Expression on Tumor-associated Macrophages Is an Independent Prognostic Factor in Stage I Lung Adenocarcinoma.

作者信息

Yoshida Chihiro, Kadota Kyuichi, Ibuki Emi, Ishikawa Ryou, Haba Reiji, Yajima Toshiki

机构信息

Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Department of General Thoracic Surgery, Kochi Health Sciences Center, Kochi, Japan.

出版信息

Anticancer Res. 2024 Mar;44(3):1289-1297. doi: 10.21873/anticanres.16924.

Abstract

BACKGROUND/AIM: Prognostic indicators for postoperative lung adenocarcinoma are elusive. The interaction between CD24 on tumor cells and sialic-acid-binding Ig-like lectin 10 (Siglec10) on tumor-associated macrophages (TAMs) is implicated in immune evasion in distinct tumors. However, the therapeutic significance of phagocytic checkpoints in lung adenocarcinoma remains unknown. We aimed to investigate the clinical relevance and prognostic significance of phagocytosis checkpoints mediated by Siglec10 in TAMs of patients with lung adenocarcinoma who underwent curative resection.

PATIENTS AND METHODS

In this single-center retrospective study, we analyzed the data of 423 patients with stage I lung adenocarcinoma resected between 1999 and 2016. Tissue microarrays were constructed, and CD24, CD68, and Siglec10 immunohistochemistry was performed. Additionally, we assessed the clinical significance and prognostic associations of these markers.

RESULTS

CD24 expression was higher in the Siglec10-high expression group than that in the -low expression group. Multivariate analysis showed that combined high Siglec10 and CD24 expression was an independent predictor of recurrence-free probability. The combined high Siglec10 and CD68 expression was a significant independent predictor of overall survival. Univariate analysis demonstrated that the 5-year probability of post-recurrence survival of patients with combined high Siglec10 and CD68 expression was lower than that of the other patients.

CONCLUSION

High TAM Siglec10 expression and tumor CD24 expression are correlated, and the high Siglec10+CD24 combination is a major risk factor for recurrence. CD68+Siglec10 TAMs are important prognostic factors. Siglec10 expression on TAMs is essential for tumor microenvironment immunoregulation and offers a promising new immunotherapeutic approach for lung adenocarcinoma.

摘要

背景/目的:术后肺腺癌的预后指标尚不明确。肿瘤细胞上的CD24与肿瘤相关巨噬细胞(TAM)上的唾液酸结合免疫球蛋白样凝集素10(Siglec10)之间的相互作用与不同肿瘤的免疫逃逸有关。然而,吞噬检查点在肺腺癌中的治疗意义仍不清楚。我们旨在研究Siglec10介导的吞噬检查点在接受根治性切除的肺腺癌患者TAM中的临床相关性和预后意义。

患者与方法

在这项单中心回顾性研究中,我们分析了1999年至2016年间切除的423例I期肺腺癌患者的数据。构建组织微阵列,并进行CD24、CD68和Siglec10免疫组织化学检测。此外,我们评估了这些标志物的临床意义和预后相关性。

结果

Siglec10高表达组的CD24表达高于低表达组。多变量分析显示,Siglec10和CD24联合高表达是无复发生存概率的独立预测因子。Siglec10和CD68联合高表达是总生存的显著独立预测因子。单变量分析表明,Siglec10和CD68联合高表达患者的复发后5年生存率低于其他患者。

结论

TAM中Siglec10高表达与肿瘤CD24表达相关,Siglec10+CD24高表达组合是复发的主要危险因素。CD68+Siglec10 TAM是重要的预后因素。TAM上的Siglec10表达对肿瘤微环境免疫调节至关重要,并为肺腺癌提供了一种有前景的新免疫治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验